The state of New Jersey currently has 419 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including New Brunswick, Hackensack, Newark and Morristown.
Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Recruiting
The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). The hypothesis for this trial is that cabozantinib has anti-tumor activity in a molecularly-selected group of patients with CRPC.
Gender:
Male
Ages:
Between 18 years and 99 years
Trial Updated:
01/16/2024
Locations: New Jersey Urology/Summit Medical Group, Saddle Brook, New Jersey
Conditions: Prostate Cancer
A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer
Recruiting
The researchers are doing this study to find out whether copanlisib in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/11/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Prostate Cancer
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Recruiting
The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. The exercise therapy in this study will be regular home-based walking sessions on a treadmill, and that therapy will be assigned by an exercise physiologist (a medical professional who studies how exercise affects the human body). Some participants in this study will have the assigned exercise therapy, and some participa... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer
Recruiting
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +2 locations
Conditions: Mesonephric Gynecologic Cancer
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
Recruiting
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: Cooper Hospital University Medical Center, Camden, New Jersey
Conditions: Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Gut and Intratumoral Microbiome Effect on the Neoadjuvant Chemotherapy-induced Immunosurveillance in Triple Negative Breast Cancer
Recruiting
The probability of pCR in TNBC patients receiving standard of care neoadjuvant chemotherapy treatment is associated with the dominance of specific intestinal and intratumoral microbiota that promote anti-tumor immunosurveillance.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/08/2024
Locations: Hackensack Meridian Health, Hackensack, New Jersey
Conditions: Triple Negative Breast Cancer
Assessing Social Determinants of Health to Increase Cancer Screening
Recruiting
A multilevel lung screening intervention that pairs Social Determinants of Health (SDoH) screening and referral with a tailored health communication and decision support tool for lung screening has the potential to significantly impact lung screening uptake among at-risk individuals in the community, particularly among those who face barriers related to SDoH. In addition, findings will advance the understanding of effective strategies for improving lung screening and prevention efforts in non-tr... Read More
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/05/2024
Locations: Hackensack Meridian Health - Center for Discovery and Innovation, Nutley, New Jersey
Conditions: Lung Cancer
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer
Recruiting
This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/05/2024
Locations: The Valley Hosptial, Inc. 411, Ridgewood, New Jersey
Conditions: Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
The INSPIRE-Lung Study
Recruiting
LungTalk and leveraging Facebook-targeted Advertisement (FBTA) addresses the call to develop and test multi-level, cancer communication interventions using innovative methods and designs. The study's long term goal is to increase lung cancer screening uptake among appropriate, high-risk individuals nationwide.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
01/05/2024
Locations: Hackensack Meridian Health - Center for Discovery and Innovation, Nutley, New Jersey
Conditions: Lung Cancer
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
Recruiting
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
A Study of Cognitive Health in Survivors of Prostate Cancer
Recruiting
The purpose of this study is to collect information that may help the researchers understand the relationship between prostate cancer survivors' experiences of cancer-related cognitive dysfunction (CRCD) and their other conditions (co-morbid factors), including anxiety, depression, and insomnia. The researchers will also find out how additional things may contribute to CRCD, including social factors, the characteristics of participants' prostate cancer, and the type of cancer treatment or other... Read More
Gender:
Male
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +2 locations
Conditions: Prostate Cancer, Survivorship
Novel Imaging Technique to Assess Gynecologic Cancer
Recruiting
This study will test a new type of DCE (dynamic contrast-enhanced) MRI (magnetic resonance imaging) to see whether, compared with traditional MRI, it produces better images that provide more information about tumors, which may help doctors make better decisions about treating women who have gynecologic cancer. MRI is commonly used to detect and evaluate many types of cancer, but its slow processing speed and the risk that images will be blurred if the patient moves inside the scanner can limit... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
01/03/2024
Locations: Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey
Conditions: Gynecologic Cancer